Life sciences company Revvity will report earnings Tuesday before the bell. Last quarter, Revvity missed analysts' revenue expectations, reporting revenues of $686.9 million, up 9.3% year on year, with full-year revenue and EPS guidance significantly below estimates. For this quarter, analysts expect revenue to grow 3.9% year on year, a reversal from the 1.6% decline in the same quarter last year. Peers Avantor and Thermo Fisher have already reported Q2 results, with Avantor posting flat revenue that beat expectations by 4.9% and Thermo Fisher reporting a 10.5% revenue increase that topped estimates by 2.4%. Revvity's stock price was unchanged over the last month and heads into earnings with an average analyst price target of $117.13 compared to the current share price of $112.52.
Revvity Inc.Revvity is the subject, but the article only previews earnings without providing actual results or guidance.
Avantor Inc
Thermo Fisher Scientific Inc